Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Liquid Biopsy Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The liquid biopsy market has experienced significant expansion in recent years. It is anticipated to increase from $1.46 billion in 2025 to $1.71 billion in 2026, showing a compound annual growth rate (CAGR) of 17.3%. The historical growth of this market can be attributed to factors such as the limitations of traditional tissue biopsy procedures, the rising global incidence of cancer, the early adoption of blood-based diagnostics, advancements in molecular biology techniques, and an increasing focus on early cancer diagnosis.
The liquid biopsy market is projected to experience swift expansion over the coming years. By 2030, its value is anticipated to reach $3.11 billion, demonstrating a compound annual growth rate (CAGR) of 16.2%. This growth during the forecast period stems from factors such as heightened demand for precision oncology, greater integration into routine cancer screening, broader uses in recurrence surveillance, an increase in oncology diagnostic expenditures, and enhanced understanding among healthcare providers and individuals. Key developments during this timeframe encompass the growing acceptance of non-invasive cancer diagnostics, the increasing utilization of liquid biopsy for detecting cancer at early stages, a surging need for real-time treatment tracking, the extension of liquid biopsy into personalized oncology approaches, and its increasing clinical recognition as a substitute for tissue biopsy.
Get A Free Sample Report With In-Depth Market Insights:
Liquid Biopsy Market Growth Catalysts And Demand Drivers
Enhanced government financial support for the advancement of cancer detection is a primary factor driving the expansion of the liquid biopsy market. This funding is largely attributed to the increasing worldwide burden of cancer, the critical need for early diagnosis to improve treatment results, and a focus on reducing healthcare costs through innovative diagnostic technologies. Government funding plays a crucial role for liquid biopsy by accelerating research and development initiatives, supporting clinical trials, and fostering the adoption of advanced, non-invasive diagnostic technologies, thereby enhancing early cancer detection and personalized treatment strategies. For instance, in October 2024, gov.UK, a UK-based government website, announced that a total of £118 ($150.38) million has been allocated to UK Research and Innovation, with £54 million originating from the government and £64 ($81.55) million from partners. Consequently, the rise in government funding for advancing cancer detection is propelling the growth of the liquid biopsy market.
Liquid Biopsy Market Segment Analysis Spotlighting Growth Areas
The liquid biopsy market covered in this report is segmented –
1) By Product: Assay Kits, Instruments, Services
2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring
3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers
Subsegments:
1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays
2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments
3) By Services: Testing Services, Data Analysis Services, Laboratory Services
Liquid Biopsy Market Trends Shaping Long-Term Demand
Companies operating within the liquid biopsy market are prioritizing the creation of advanced solutions, notably comprehensive circulating tumor DNA (ctDNA) genomic-profiling assays. These developments aim to accelerate noninvasive cancer profiling, facilitate quicker therapeutic decisions, and broaden access to precision oncology when tissue samples are limited or unattainable. A ctDNA comprehensive genomic-profiling assay operates by analyzing tumor-derived cell-free DNA fragments found in the bloodstream to identify somatic small variants, copy-number changes, insertions/deletions, and immuno-oncology signatures (e.g., bTMB and bMSI). This offers more extensive tumor insights without the invasiveness, sampling bias, or longer turnaround times associated with traditional tissue biopsies. For instance, in November 2023, Illumina Inc., a US–based sequencing and genomics company, introduced TruSight Oncology 500 ctDNA v2. This research-use liquid biopsy panel is designed for noninvasive genomic profiling of solid tumors, incorporating an expanded hybrid-capture panel with DRAGEN bioinformatics to sequence 523 biomarkers from low cfDNA input. The assay efficiently enriches and detects SVs, CNVs, indels, and immuno-oncology metrics with high analytical performance, provides streamlined workflows featuring a single hybridization step and a turnaround time of less than 4 days, and is compatible with NovaSeq systems and upcoming automation. It supports use when tissue is unavailable or delayed, complements tissue testing, and enables broad pan-cancer research and trial screening, offering faster insights, suitability for low-input samples, and easier adoption across distributed lab environments.
Liquid Biopsy Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.
View The Full Liquid Biopsy Market Report:
Liquid Biopsy Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the liquid biopsy market in 2025. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
